Christine Durier

Reframing analytical treatment interruption through participants' and decliners' eyes: insights from an HIV remission trial.

Journal: AIDS (London, England)

Published: March 26, 2026

Ancestral Wuhan SARS-CoV-2 anti-spike CD4+ T cells predict protection from symptomatic omicron breakthrough infection.

Journal: Vaccine

Published: January 03, 2026

Characteristics of Human Metapneumovirus Infection Compared to Respiratory Syncytial Virus and Influenza Infections in Adults Hospitalized for Influenza-Like Illness in France, 2012-2022.

Journal: The Journal of infectious diseases

Published: July 16, 2025

Serum and Salivary IgG and IgA Response After COVID-19 Messenger RNA Vaccination.

Journal: JAMA network open

Published: April 23, 2024

Cytokine profile of anti-spike CD4+T cells predicts humoral and CD8+T cell responses after anti-SARS-CoV-2 mRNA vaccination.

Journal: iScience

Published: April 08, 2024

Vaccine effectiveness against COVID-19 hospitalisation in adults (≥ 20 years) during Omicron-dominant circulation: I-MOVE-COVID-19 and VEBIS SARI VE networks, Europe, 2021 to 2022.

Journal: Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin

Published: November 24, 2023

Incidence of COVID-19 mRNA vaccine symptomatic breakthrough infections during Omicron circulation in adults with or without infection prior to vaccination.

Journal: Infectious diseases now

Published: October 13, 2023

A prospective national cohort evaluating ring MVA vaccination as post-exposure prophylaxis for monkeypox.

Journal: Nature medicine

Published: July 13, 2022

Neutralizing antibodies against SARS-CoV-2 variants following mRNA booster vaccination in adults older than 65 years.

Journal: Scientific reports

Published: June 02, 2022

A comparison of Sars-Cov-2 vaccine platforms: the CoviCompare project.

Journal: Nature medicine

Published: May 05, 2022

A 5-year neutralizing immune response to yellow fever vaccine in HIV-infected and HIV-uninfected adults.

Journal: AIDS (London, England)

Published: December 22, 2021

Immunoglobulin-free strategy to prevent HBV mother-to-child transmission in Cambodia (TA-PROHM): a single-arm, multicentre, phase 4 trial.

Journal: The Lancet. Infectious diseases

Published: December 08, 2021

Reframing analytical treatment interruption through participants' and decliners' eyes: insights from an HIV remission trial.

Reframing analytical treatment interruption through participants' and decliners' eyes: insights from an HIV remission trial.

Ancestral Wuhan SARS-CoV-2 anti-spike CD4+ T cells predict protection from symptomatic omicron breakthrough infection.

Ancestral Wuhan SARS-CoV-2 anti-spike CD4+ T cells predict protection from symptomatic omicron breakthrough infection.

Characteristics of Human Metapneumovirus Infection Compared to Respiratory Syncytial Virus and Influenza Infections in Adults Hospitalized for Influenza-Like Illness in France, 2012-2022.

Characteristics of Human Metapneumovirus Infection Compared to Respiratory Syncytial Virus and Influenza Infections in Adults Hospitalized for Influenza-Like Illness in France, 2012-2022.

Serum and Salivary IgG and IgA Response After COVID-19 Messenger RNA Vaccination.

Serum and Salivary IgG and IgA Response After COVID-19 Messenger RNA Vaccination.

Cytokine profile of anti-spike CD4+T cells predicts humoral and CD8+T cell responses after anti-SARS-CoV-2 mRNA vaccination.

Cytokine profile of anti-spike CD4+T cells predicts humoral and CD8+T cell responses after anti-SARS-CoV-2 mRNA vaccination.

Vaccine effectiveness against COVID-19 hospitalisation in adults (≥ 20 years) during Omicron-dominant circulation: I-MOVE-COVID-19 and VEBIS SARI VE networks, Europe, 2021 to 2022.

Vaccine effectiveness against COVID-19 hospitalisation in adults (≥ 20 years) during Omicron-dominant circulation: I-MOVE-COVID-19 and VEBIS SARI VE networks, Europe, 2021 to 2022.

Incidence of COVID-19 mRNA vaccine symptomatic breakthrough infections during Omicron circulation in adults with or without infection prior to vaccination.

Incidence of COVID-19 mRNA vaccine symptomatic breakthrough infections during Omicron circulation in adults with or without infection prior to vaccination.

A prospective national cohort evaluating ring MVA vaccination as post-exposure prophylaxis for monkeypox.

A prospective national cohort evaluating ring MVA vaccination as post-exposure prophylaxis for monkeypox.

Neutralizing antibodies against SARS-CoV-2 variants following mRNA booster vaccination in adults older than 65 years.

Neutralizing antibodies against SARS-CoV-2 variants following mRNA booster vaccination in adults older than 65 years.

A comparison of Sars-Cov-2 vaccine platforms: the CoviCompare project.

A comparison of Sars-Cov-2 vaccine platforms: the CoviCompare project.

A 5-year neutralizing immune response to yellow fever vaccine in HIV-infected and HIV-uninfected adults.

A 5-year neutralizing immune response to yellow fever vaccine in HIV-infected and HIV-uninfected adults.

Immunoglobulin-free strategy to prevent HBV mother-to-child transmission in Cambodia (TA-PROHM): a single-arm, multicentre, phase 4 trial.

Immunoglobulin-free strategy to prevent HBV mother-to-child transmission in Cambodia (TA-PROHM): a single-arm, multicentre, phase 4 trial.

Vaccine effectiveness against COVID-19 hospitalisation in adults (≥ 20 years) during Omicron-dominant circulation: I-MOVE-COVID-19 and VEBIS SARI VE networks, Europe, 2021 to 2022.

Vaccine effectiveness against COVID-19 hospitalisation in adults (≥ 20 years) during Omicron-dominant circulation: I-MOVE-COVID-19 and VEBIS SARI VE networks, Europe, 2021 to 2022.